- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Wayne Winegarden, PhD, on Downside of Importing Drugs From Canada
We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why the FDA’s implementation of the Safe Importation Action Plan is controversial.
Earlier this year, President Trump signed 4 executive orders designed to lower the cost of prescription drugs. One of those orders allows for insulins and other medications, such as biologics, to be imported from countries like Canada, where the same products sold in the United States are sold at lower prices. Since the signing, the FDA has officially adopted a final rule to implement the plans.
The rule, dubbed as the Safe Importation Action Plan, permits states and indigenous tribes as well as some pharmacies and wholesalers permission to submit importation program proposals to the FDA for review and authorization. Although HHS and federal officials believe the plan has real potential to lower costs, some experts see the plan as both ineffective and possibly dangerous.
We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why this plan is so controversial and what steps should be taken instead to help lower drug costs.
To read more on Wayne’s thoughts of this plan, click here.
To learn more about the Safe Importation Action Plan, click here.
To learn more about President Trump’s executive orders, click here.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
